EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Implementation of pharmacist‐led chronic kidney disease screening in Australian community pharmacies: feasibility and characteristics of the screened population

Ayana Korsa iD, Ines Krass, Mimi Truong iD, Linda Do iD, Jing Xin Goh, Kamal Sud iD, David W Johnson iD, Sanjyot Vagholkar, Rita McMorrow, Lukas Kairaitis iD, Judy Mullan iD, Anh Tran iD und 6 weitere

Internal Medicine Journal · 02.11.2026

DOI: 10.1111/imj.70692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, online erschienen am 02.11.2026. Verfasst von Ayana Korsa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Research Future Fund (MRFF) under Australian Government's Primary Healthcare Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Chronic Kidney Disease Screening and Quality Use of Medicines trial aimed to improve chronic kidney disease (CKD) detection and optimise medication use in Australia. This analysis evaluates the feasibility of pharmacy‐based screening for identifying individuals at risk of CKD and reports participant baseline characteristics.

Methods

Eligible participants for the trial were aged 35–74 years and had ≥1 CKD risk factor. The intervention group received a QKidney® risk assessment, point‐of‐care test (POCT) and medication reviews, while the control group received the risk assessment only. QKidney® scores and blood pressure (BP) classified 5‐year CKD risk as low, moderate or high. Intervention participants at moderate‐to‐high risk underwent POCT of serum creatinine to estimate estimated glomerular filtration rate (eGFR). Reduced kidney function was defined as eGFR < 60 mL/min/1.73 m 2 and prevalence was compared with Australian National Health Measures Survey 2022–2024 estimates. Data were analysed in Statistical Package for Social Sciences (version 31) using descriptive statistics.

Results

Of the 1486 participants recruited between March 2023 and December 2024, 1189 were included in this analysis (550 (46%) intervention, 639 (54%) control). Risk assessment was completed in 99.9% of participants using QKidney® and in 100% using BP. A POCT was performed for 84% of intervention participants at moderate to high risk. Of those fulfilling pre‐defined general practice referral criteria, 73% were referred. Overall, 68% of trial participants were at moderate to high CKD risk (59% identified by QKidney® and 30% by BP). Additionally, 21% had reduced kidney function based on POCT results – substantially higher than the national estimates (5.2%).

Conclusions

Pharmacy‐based targeted screening was feasible for identifying individuals at risk of developing CKD and could strengthen early detection efforts in Australia.

Schlagwörter

Stichwörter der Autor:innen

Australiachronic kidney diseasecommunity pharmacyearly detectiontargeted screening

Autor:innen und Institutionen

  • Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Pharmacy, Blacktown Hospital, Sydney, New South Wales, Australia.
  • Nepean Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Nepean Kidney Research Centre, Department of Renal Medicine, Nepean Hospital, Sydney, New South Wales, Australia.
  • Centre for Kidney Disease Research, The University of Queensland at Princess Alexandra Hospital, Brisbane, Queensland, Australia.
  • Department of Kidney and Transplant Services, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

ORCID-Profile: Ayana Korsa, Mimi Truong, Linda Do, Kamal Sud, David W Johnson, Lukas Kairaitis, Judy Mullan, Anh Tran, Connie Van, Natasa Gisev, Breonny Robson, Victoria Kim, Ronald L Castelino

Förderung

  • Medical Research Future Fund (MRFF) under Australian Government's Primary Healthcare Initiative

Zitieren

APA

Korsa, A., Krass, I., Truong, M., Do, L., Goh, J. X., Sud, K., Johnson, D. W., Vagholkar, S., McMorrow, R., Kairaitis, L., Mullan, J., Tran, A., Van, C., Tesfaye, W., Gisev, N., Robson, B., Kim, V., & Castelino, R. L. (2026). Implementation of pharmacist‐led chronic kidney disease screening in Australian community pharmacies: feasibility and characteristics of the screened population. Internal Medicine Journal. https://doi.org/10.1111/imj.70692

Vancouver

Korsa A, Krass I, Truong M, Do L, Goh JX, Sud K, et al. Implementation of pharmacist‐led chronic kidney disease screening in Australian community pharmacies: feasibility and characteristics of the screened population. Internal Medicine Journal. 2026. doi:10.1111/imj.70692

BibTeX
@article{Korsa2026,
  author = {Korsa, Ayana and Krass, Ines and Truong, Mimi and Do, Linda and Goh, Jing Xin and Sud, Kamal and Johnson, David W and Vagholkar, Sanjyot and McMorrow, Rita and Kairaitis, Lukas and Mullan, Judy and Tran, Anh and Van, Connie and Tesfaye, Wubshet and Gisev, Natasa and Robson, Breonny and Kim, Victoria and Castelino, Ronald L},
  title = {Implementation of pharmacist‐led chronic kidney disease screening in Australian community pharmacies: feasibility and characteristics of the screened population},
  journal = {Internal Medicine Journal},
  year = {2026},
  doi = {10.1111/imj.70692}
}
Kostenlos starten →